Colin Stott

3.1k total citations · 1 hit paper
26 papers, 2.4k citations indexed

About

Colin Stott is a scholar working on Pharmacology, Cellular and Molecular Neuroscience and Psychiatry and Mental health. According to data from OpenAlex, Colin Stott has authored 26 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pharmacology, 6 papers in Cellular and Molecular Neuroscience and 5 papers in Psychiatry and Mental health. Recurrent topics in Colin Stott's work include Cannabis and Cannabinoid Research (23 papers), Neuroscience and Neuropharmacology Research (4 papers) and Neurotransmitter Receptor Influence on Behavior (4 papers). Colin Stott is often cited by papers focused on Cannabis and Cannabinoid Research (23 papers), Neuroscience and Neuropharmacology Research (4 papers) and Neurotransmitter Receptor Influence on Behavior (4 papers). Colin Stott collaborates with scholars based in United Kingdom, Italy and United States. Colin Stott's co-authors include Vincenzo Di Marzo, Luciano De Petrocellis, Aniello Schiano Moriello, Alessia Ligresti, Stefania Petrosino, Marco Allarà, Tiziana Bisogno, Geoffrey W. Guy, P. Duncombe and Stephen Wright and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and Diabetes Care.

In The Last Decade

Colin Stott

26 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes

2010 735 citations Luciano De Petrocellis, Alessia Ligresti et al. British Journal of Pharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Colin Stott United Kingdom	18	1.8k	598	392	352	254	26	2.4k
Neta Rimmerman United States	22	1.5k 0.8×	608 1.0×	207 0.5×	247 0.7×	126 0.5×	28	2.8k
Mariapia Colleoni Italy	26	1.7k 0.9×	919 1.5×	258 0.7×	247 0.7×	271 1.1×	37	2.8k
Fabio Arturo Iannotti Italy	30	1.6k 0.8×	707 1.2×	227 0.6×	302 0.9×	119 0.5×	71	2.8k
Marnie Duncan United Kingdom	21	2.6k 1.4×	1.2k 2.1×	425 1.1×	375 1.1×	127 0.5×	23	3.0k
James J. Burston United Kingdom	28	2.6k 1.4×	1.3k 2.1×	232 0.6×	394 1.1×	215 0.8×	51	3.6k
Katarzyna Starowicz Poland	33	2.3k 1.2×	1.3k 2.1×	294 0.8×	362 1.0×	128 0.5×	68	3.8k
Daniele De Filippis Italy	30	2.2k 1.2×	864 1.4×	505 1.3×	330 0.9×	120 0.5×	41	3.3k
Michael D. Randall United Kingdom	37	1.8k 1.0×	621 1.0×	144 0.4×	785 2.2×	628 2.5×	95	4.0k
Susanna Tchilibon United States	16	1.6k 0.9×	861 1.4×	258 0.7×	223 0.6×	79 0.3×	18	2.2k
Gabriella Giagnoni Italy	23	1.8k 1.0×	1.1k 1.8×	237 0.6×	199 0.6×	139 0.5×	56	2.7k

Countries citing papers authored by Colin Stott

Since Specialization

Citations

This map shows the geographic impact of Colin Stott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colin Stott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colin Stott more than expected).

Fields of papers citing papers by Colin Stott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Colin Stott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colin Stott. The network helps show where Colin Stott may publish in the future.

Co-authorship network of co-authors of Colin Stott

This figure shows the co-authorship network connecting the top 25 collaborators of Colin Stott. A scholar is included among the top collaborators of Colin Stott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Colin Stott. Colin Stott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stott, Colin, et al.. (2019). Anticonvulsive Properties of Cannabidiol in a Model of Generalized Seizure Are Transient Receptor Potential Vanilloid 1 Dependent. Cannabis and Cannabinoid Research. 5(2). 145–149. 47 indexed citations

Nichol, Kathryn, et al.. (2019). The proposed multimodal mechanism of action of cannabidiol (CBD) in epilepsy: modulation of intracellular calcium and adenosine-mediated signaling (P5.5-007). Neurology. 92(15_supplement). 9 indexed citations

Whalley, Benjamin J., et al.. (2018). Antiseizure properties of cannabidiol (CBD) are attenuated in the absence of transient receptor potential vanilloid 1 (TRPV1) receptors (S53.004). Neurology. 90(15_supplement). 5 indexed citations

Stott, Colin, et al.. (2017). The Effect of Cannabidiol on Human CNS-Expressed Voltage-Gated Sodium Channels (P1.228). Neurology. 88(16_supplement). 1 indexed citations

Stott, Colin, et al.. (2017). Cannabidiol Does Not Convert to Δ ⁹ -Tetrahydrocannabinol in an In Vivo Animal Model. Cannabis and Cannabinoid Research. 2(1). 282–287. 16 indexed citations

Jadoon, Khalid, S. Ratcliffe, David A. Barrett, et al.. (2016). Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. Diabetes Care. 39(10). 1777–1786. 179 indexed citations

Jones, Nicholas A., Thomas G. Hill, Colin Stott, & Stephen Wright. (2016). Assessment of the Anticonvulsant Effects and Tolerability of GW Pharmaceuticals’ Cannabidiol in the Anticonvulsant Screening Program (P2.038). Neurology. 86(16_supplement). 2 indexed citations

Deiana, Serena, Akihito Watanabe, Yuki Yamasaki, et al.. (2015). MK-801-induced deficits in social recognition in rats. Behavioural Pharmacology. 26(8). 748–765. 34 indexed citations

Sellers, Edward M., Kerri A. Schoedel, Myroslava K. Romach, et al.. (2013). A Multiple‐Dose, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray. Clinical Pharmacology in Drug Development. 2(3). 285–294. 29 indexed citations

10.

Stott, Colin, Linda R. White, Stephen Wright, Darren Wilbraham, & Geoffrey W. Guy. (2013). A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. SpringerPlus. 2(1). 236–236. 94 indexed citations

11.

Wargent, Edward T., Mohamed S. Zaïbi, Cristoforo Silvestri, et al.. (2013). The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutrition and Diabetes. 3(5). e68–e68. 76 indexed citations

12.

Stott, Colin, Linda R. White, Stephen Wright, Darren Wilbraham, & Geoffrey W. Guy. (2012). A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray. European Journal of Clinical Pharmacology. 69(4). 825–834. 63 indexed citations

13.

Stott, Colin, Linda R. White, Stephen Wright, Darren Wilbraham, & Geoffrey W. Guy. (2012). A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. European Journal of Clinical Pharmacology. 69(5). 1135–1147. 85 indexed citations

14.

Petrocellis, Luciano De, Alessia Ligresti, Aniello Schiano Moriello, et al.. (2012). Non‐THC cannabinoids inhibit prostate carcinoma growthin vitroandin vivo: pro‐apoptotic effects and underlying mechanisms. British Journal of Pharmacology. 168(1). 79–102. 160 indexed citations

15.

Stott, Colin, Stephen Wright, Geoffrey W. Guy, et al.. (2012). Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis. SHILAP Revista de lepidopterología. 2012. 1–7. 39 indexed citations

16.

Petrocellis, Luciano De, Pierangelo Orlando, Aniello Schiano Moriello, et al.. (2011). Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiologica. 204(2). 255–266. 242 indexed citations

17.

Petrocellis, Luciano De, Alessia Ligresti, Aniello Schiano Moriello, et al.. (2010). Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology. 163(7). 1479–1494. 735 indexed citations breakdown →

18.

Farrar, John T., Andrea B. Troxel, Colin Stott, P. Duncombe, & Mark P. Jensen. (2008). Validity, reliability, and clinical importance of change in a 0—10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clinical Therapeutics. 30(5). 974–985. 196 indexed citations

19.

Compston, Juliet, Colin Stott, R.A. Hannon, et al.. (2005). Changes in bone mineral density, body composition and biochemical markers of bone turnover during weight gain in adolescents with severe anorexia nervosa: a 1-year prospective study. Osteoporosis International. 17(1). 77–84. 52 indexed citations

20.

Stott, Colin & Geoffrey W. Guy. (2004). Cannabinoids for the pharmaceutical industry. Euphytica. 140(1-2). 83–93. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact